Document Detail

Cost-Effectiveness of Cytochrome P450 2C19 Genotype Screening for Selection of Antiplatelet Therapy with Clopidogrel or Prasugrel.
MedLine Citation:
PMID:  22411359     Owner:  NLM     Status:  Publisher    
STUDY OBJECTIVE: To estimate the cost-effectiveness of genotype-guided selection of antiplatelet therapy compared with selecting clopidogrel or prasugrel irrespective of genotype. DESIGN: Decision model based on event occurrence in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis in Myocardial Infarction (TRITON-TIMI) 38. PATIENTS: Simulated cohort of patients with acute coronary syndrome scheduled to undergo percutaneous coronary intervention (PCI), consisting of three arms: those receiving genotype-guided antiplatelet therapy with clopidogrel or prasugrel, those receiving clopidogrel regardless of genotype, and those receiving prasugrel regardless of genotype. MEASUREMENTS AND MAIN RESULTS: All three arms of the model incorporated the probability that patients would experience a cardiovascular event (death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke), a bleeding event (major or minor bleeding), or no event while receiving antiplatelet therapy during the 15 months after the scheduled PCI. The cytochrome P450 (CYP) 2C19 genotype determined antiplatelet drug selection in the genotyping group. Cost-effectiveness was expressed as the incremental cost-effectiveness ratio (ICER) for each event avoided in the genotype-guided therapy arm versus the other two arms. Genotype-guided antiplatelet therapy was dominant, or more effective and less costly, when compared with the selection of clopidogrel (ICER -$6760 [95% confidence interval (CI) -$6720 to -$6790]) or prasugrel (ICER -$11,710 [95% CI -$11,480 to -$11,950]) for all patients without regard to genotype. Genotype-guided therapy that included generic clopidogrel was dominant to prasugrel for all patients (ICER -$27,160 [95% CI -$27,890 to -$26,420]). Cost savings were not evident when genotype-guided therapy that included generic clopidogrel was compared with generic clopidogrel for all patients (ICER -$2300 [95% CI $2290 to $2320]). CONCLUSION: Genotype-guided antiplatelet therapy selection may be more cost-effective and may provide more clinical value due to fewer adverse outcomes.
Emily S Reese; C Daniel Mullins; Amber L Beitelshees; Eberechukwu Onukwugha
Related Documents :
16125049 - Renin-angiotensin system modulation: the weight of evidence.
1804629 - Modulation of coronary circulation and the cardiac matrix by the renin-angiotensin system.
21855019 - Reprinted article "the fate of the claudicant-a prospective study of 1969 claudicants".
22077909 - Abciximab and heparin versus bivalirudin for non-st-elevation myocardial infarction.
21712169 - Ivabradine, a novel heart rate slower: is it a sword of double blades in patients with ...
22098399 - Role of left ventricular dyssynchrony in predicting remodeling after st elevation myoca...
3214119 - Creatine determinations as an early marker for the diagnosis of acute myocardial infarc...
1904189 - Long-term effect of thrombolytic therapy on left ventricular ejection fraction after ac...
21283079 - Coronary vein infusion of multipotent stromal cells from bone marrow preserves cardiac ...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2012-3-12
Journal Detail:
Title:  Pharmacotherapy     Volume:  -     ISSN:  1875-9114     ISO Abbreviation:  -     Publication Date:  2012 Mar 
Date Detail:
Created Date:  2012-3-13     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8111305     Medline TA:  Pharmacotherapy     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Copyright Information:
© 2012 Pharmacotherapy Publications, Inc.
Schools of Pharmacy, University of Maryland, Baltimore, Maryland.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Mesotoga prima gen. nov., sp. nov., the first described mesophilic species of the Thermotogales.
Next Document:  [Optimization of energy intake in artificial nutrition: second lecture Jesús Culebras].